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Abstract
Background: Alterations in the highly penetrant cancer susceptibility gene BRCA1 are responsible for the
majority of hereditary breast and/or ovarian cancers. However, the number of detected germline
mutations has been lower than expected based upon genetic linkage data. Undetected deleterious
mutations in the BRCA1 gene in some high-risk families could be due to the presence of intragenic
rearrangements as deletions, duplications or insertions spanning whole exons. Standard PCR-based
screening methods are mainly focused on detecting point mutations and small insertions/deletions, but
large rearrangements might escape detection.
The purpose of this study was to determine the type and frequency of large genomic rearrangements in
the BRCA1 gene in hereditary breast and ovarian cancer cases in the Czech Republic.
Methods:  Multiplex ligation-dependent probe amplification (MLPA) was used to examine BRCA1
rearrangements in 172 unrelated patients with hereditary breast and/or ovarian cancer syndrome without
finding deleterious mutation after complete screening of whole coding regions of BRCA1/2 genes. Positive
MLPA results were confirmed and located by long-range PCR. The breakpoints of detected
rearrangements were characterized by sequencing.
Results: Six different large deletions in the BRCA1 gene were identified in 10 out of 172 unrelated high-
risk patients: exons 1A/1B and 2 deletion; partial deletion of exon 11 and exon 12; exons 18 and 19
deletion; exon 20 deletion; exons 21 and 22 deletion; and deletion of exons 5 to 14. The breakpoint
junctions were localized and further characterized. Destabilization and global unfolding of the mutated
BRCT domains explain the molecular and genetic defects associated with the exon 20 in-frame deletion
and the exon 21 and 22 in-frame deletion, respectively.
Conclusion: Using MLPA, mutations were detected in 6% of high-risk patients previously designated as
BRCA1/2 mutation-negative. The breakpoints of five out of six large deletions detected in Czech patients
are novel. Screening for large genomic rearrangements in the BRCA1 gene in the Czech high-risk patients
is highly supported by this study.
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Background
Breast cancer is the most commonly diagnosed cancer in
women in Europe today. A hereditary form of breast can-
cer is characterized by young age onset, increased risk of
bilateral breast cancer, and its being frequently in associa-
tion with ovarian cancer. The existence of an autosomal
dominant pattern of inheritance accounting for 5–10% of
the breast cancer cases has been demonstrated [1]. Germ-
line mutations in BRCA1 (OMIM#113705, Online Men-
delian Inheritance in Man) and BRCA2 (OMIM#600185)
genes are responsible for an important fraction of heredi-
tary breast and ovarian cancers [2]. A few hundred differ-
ent mutations associated with inherited predisposition to
breast and ovarian cancers have been identified in the
BRCA1 and BRCA2 genes, as described at the Breast Can-
cer Information Core internet web site (BIC database) [3].
Most reported germline deleterious mutations are non-
sense substitutions and small deletions/insertions causing
truncations of BRCA1/2  proteins. In most populations
tested, the observed frequencies of BRCA1 variations in
high-risk breast and/or ovarian cancer families have been
described as lower than predicted by linkage analysis.
Pathogenic mutations in the coding region or in splice
sites of the BRCA1 gene were found in approximately two-
thirds of BRCA1-linked families [2]. This finding suggests
that methods generally used for mutation scanning fail to
detect certain types of BRCA1 germline defects, such as
large intragenic rearrangements. Most of the screening
methods based on the PCR of genomic DNA are qualita-
tive rather than quantitative [4]. Partial or complete exon
loss or amplification might be overlooked because of the
presence of a wild-type allele that gives rise to a positive
PCR signal and therefore a possible false-negative result.
Several approaches have been used for detecting BRCA1
rearrangements: Southern blot [5-9], long-range PCR
[10], color bar coding of the BRCA1  gene on combed
DNA [11,12], semiquantitative-multiplex PCR [13,14] or
real-time PCR [15]. Recently, multiplex ligation-depend-
ent probe amplification (MLPA) has been widely used as
a highly sensitive method for detecting the relative copy
number of all BRCA1 exons in a high-throughput format
[16].
Many different BRCA1  germline rearrangements with
mapped breakpoints have been reported to date [17].
These are scattered throughout the whole gene and most
of them are deletions, but duplication, triplication or
combined deletion/insertion events also have been
described. A genetic structure of BRCA1 with extremely
high density of intronic Alu repeats and the presence of a
duplicated promoter region containing a BRCA1 pseudo-
gene upstream of the BRCA1 could provide hotspots for
unequal homologous recombination [18,19]. The pro-
portion of genomic rearrangements in the BRCA1 muta-
tion spectrum has been studied in several countries and
often was found to vary from 8 to 15% [7,20-23]. Higher
values, probably due to a strong founder effect, have been
presented by studies performed in the Netherlands and
Italy [24,25]. The majority of known rearrangements cre-
ate frame shifts that result in premature termination of
translation. Therefore, the phenotype of patients carrying
this type of mutations is not expected to be distinct from
patients with other truncating mutations. Most mutations
introducing a stop codon into BRCA1  have been
described as leading to nonsense-mediated decay of
mRNA, irrespective of their type [26]. Large deletions of
one or more exons maintaining the reading frame could
cause loss of putative functional domains of the BRCA1
protein [8]. However, no assay for the BRCA1 gene is cur-
rently available for testing the exact functional conse-
quences of such mutations.
The presence of large rearrangements in the BRCA1 gene
offers a promising outlook in clinical practice, and espe-
cially for probands with previously negative results of
BRCA1/2 mutation screening. If causative mutation is
determined, predictive testing can be performed to iden-
tify family members who may benefit from increased sur-
veillance, chemoprevention or prophylactic surgery to
reduce the risk of developing cancer [27]. The aim of this
study was to determine the frequency and type of BRCA1
intragenic rearrangements in Czech high-risk breast and/
or ovarian cancer families where no deleterious mutations
were previously found and to assess whether testing for
such rearrangements should be included in standard
mutation screening.
Methods
Patients and criteria for testing
The test group was comprised of 172 high-risk Czech fam-
ilies with hereditary breast and/or ovarian cancer syn-
drome referred for genetic testing to the Masaryk
Memorial Cancer Institute in Brno (Table 1). All tested
individuals were counseled and gave signed informed
consent. The inclusion criteria were as follow: (i) unre-
lated index patients affected by invasive breast and/or
ovarian cancer, (ii) at least three diagnoses of breast and/
or ovarian cancer in the family diagnosed at any age
(bilateral cancers were counted as two cases), and (iii) no
deleterious mutation found during complete screening of
the whole coding regions of BRCA1 and BRCA2 genes as
described by Foretova et al. [28]. This group could be
divided into two main parts consistent with the cancer
phenotype of the probands' families: the individuals
belonging to the families with at least one case of ovarian
cancer (45 patients) and those individuals from the fami-
lies with breast cancer phenotype only (127 patients).
These were further subdivided according to the number of
individuals diagnosed with breast cancer at ages under 50
years (Table 1).
Detecting large genomic rearrangements using MLPA
Relative quantification of the copy numbers of all 24
BRCA1 exons was performed by the Salsa P002 BRCA1
MLPA probe mix assay (M.R.C. Holland, Amsterdam, theBMC Medical Genetics 2007, 8:32 http://www.biomedcentral.com/1471-2350/8/32
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Netherlands) as described by the manufacturer [29]. Each
MLPA analysis was carried out on 10 samples and 2 con-
trols on a PTC-200 thermal cycler (Bio-Rad, Hercules, CA,
USA). PCR products were separated on an ALFexpress™ II
(Amersham Pharmacia Biotech, Uppsala, Sweden) or an
ABI PRISM 310 (Applied Biosystems, Foster City, USA)
instrument. A peak pattern of 34 peaks ranging in size
from 127 to 454 bp was detected [16]. The data obtained
on the capillary sequencer ABI-310 were analyzed using
GeneScan 3.1.2 Software. The peak heights were normal-
ized and deletions were suspected when the peak height
was lower than 65% of the controls. The positive MLPA
results were confirmed using new DNA samples in inde-
pendent assays. DNA sequence analysis of the appropriate
ligation sites was done in the case of single exon deletions
to eliminate the possibility of an amplification artifact or
a presence of polymorphism in ligation sites. False-posi-
tive deletions or duplications of single exons were
resolved by repeated testing of independent DNA samples
for the patient.
Confirmation and characterization of the rearrangements
Positive results detected by MLPA of two independently
drawn samples of genomic DNA were confirmed by long-
range PCR (Expand Long Template PCR System, Roche
Applied Science), conducted in accordance with the man-
ufacturer's instructions. Several pairs of primers located in
exons or introns flanking the rearrangements were used to
localize the breakpoint junctions. The GeneFisher pro-
gram was used for primer design [30]. Selected primers
used for long-range PCR of detected Czech rearrange-
ments are presented in Table 2. PCR products were sepa-
rated by agarose gel electrophoresis and visualized by
ethidium bromide staining. A smaller fragment corre-
sponding to the allele with deletion compared to the wild-
type allele was obtained in all six deletions detected in this
study. Such aberrant DNA fragments were cut out and iso-
lated from agarose gel (QIAquick gel extraction Kit, QIA-
GEN, Hilden, Germany), sequenced with appropriate
primers (ThermoSequenase Cy5 Dye Terminator Cycle
Sequencing Kit, Amersham Biosciences, UK), and ana-
lyzed on an ALFexpress™ II sequencer (Amersham Phar-
macia Biotech, Uppsala, Sweden) or an ABI 3130 genetic
analyzer (Applied Biosystems, Foster City, USA). The
Repeat Masker program was used to identify Alu
sequences at breakpoint junctions [31].
Nomenclature
Detected mutations were described at the gDNA level
according to the GenBank Database BRCA1  reference
sequence L78833 (or to the sequence of BAC clone
AC060780 in case of the deletion of 1A/1B-2 exons) and
following the recommended nomenclature system for
human gene mutations [32].
Structural interpretation of mutations
The crystal structures of the BRCT domains of the BRCA1
protein [33] (PDB-ID 1JNX) and its complexes with the
tumor suppressor p53 [34] (PDB-ID 1KZY), with the
phosphorylated bach1 peptide [35] (PDB-ID 1T29), with
the phosphopeptides [36,37] (PDB-IDs 1T2V and 1Y98),
and with the phosphorylated interacting region from
bach1 helicase [38] (PDB-ID 1T15) were inspected using
the PyMol viewer v0.99 (DeLano Scientific, LLC).
Table 1: Molecular genetic testing in 290 Czech high-risk families
Phenotype of 
families tested for 
BRCA1/2 mutations*
Number of 
families/patients
BRCA1 
mutation (%)
BRCA2 
mutation (%)
Overall 
mutation (%)
Phenotype and number of 
families tested for BRCA1 
deletions*
Number of BRCA1 
deletions detected
HBOC+HOC 105 51 (48.6%) 9 (8.6%) 60 (57.2%) HBOC 36 4
HOC 91
Σ 45 5/45 (11.1%)
5/56 ~8.93% of BRCA1 mutations
HBC 185 35 (18.9%) 23 (12.4%) 58 (31.3%) 0 × brca<50 29 -
1 × brca<50 52 1
2 × brca<50 28 1
3 × brca<50 15 -
4 × brca<50 33
Σ 127 5/127 (3.9%)
5/40 ~12.5% of BRCA1 mutations
Overall 172 10/172 (5.8%)
10/96 ~10.4% of BRCA1 mutations
Overall 290 86 (29.7%) 32 (11.0%) 118 (40.7%) 10/290 (3.4%)
*See Materials and methods, Patients and criteria for testing. Only deleterious mutations are considered. HBOC – hereditary breast and ovarian 
cancer syndrome; HOC – hereditary ovarian cancer syndrome; HBC – hereditary breast cancer syndrome.BMC Medical Genetics 2007, 8:32 http://www.biomedcentral.com/1471-2350/8/32
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Results and discussion
The MLPA analysis of genomic DNA of 172 affected indi-
viduals from high-risk families with hereditary breast and/
or ovarian cancer syndrome revealed six different dele-
tions covering 1.9–36.9 kb of the BRCA1 genomic DNA
(Figure 1, Table 3). The average age at the onset of the can-
cer diagnosis in probands with detected BRCA1 rearrange-
ments was 40 years. The effect of decreasing age at onset
of the illness in younger generations could be observed in
some families. Except for two rearrangements including
the exons 5–14 and 11–12, the deletions spanning the
exons 1A/1B-2, 18–19, 20 and 21–22 had been previously
described in the literature [6,8,19,25,39]. However, the
breakpoints of five out of six deletions detected in Czech
patients were different from those characterized previ-
ously (Table 3).
The deletion of 1A/1B-2 exons was detected by MLPA in
one family with the mother affected with ovarian cancer
at age 43 and with two relatives affected with breast cancer
at young age: her daughter at the age of 38 and her sister
at age 39. The deletion of 1A/1B-2 exons was confirmed
by long-range PCR with primers published by Puget et al.
[19] (Figure 2A). The intensive PCR product was created
only for the mutant allele and sequencing revealed the
36.9 kb deletion extending from intron 2 of the ψBRCA1
to intron 2 of the BRCA1 gene. The breakpoint region is
consistent with that reported previously by Preisler-
Adams et al. [40] and comprises 188 bp of perfect nucle-
otide homology between sequences located in the intron
2 of ψBRCA1 and intron 2 of the BRCA1 gene (Figure 2A).
Based on the BAC clone sequence AC060780, the break-
points occurred between nucleotides 71053–71240 in
ψBRCA1 and nucleotides 34118–34305 in BRCA1 intron
2 [40]. The mutant allele harbors a chimeric gene consist-
ing of the ψBRCA1 exons 1A, 1B and 2 fused to the BRCA1
Multiplex ligation-dependent probe amplification (MLPA)  electropherogram (ABI PRISM 310 genetic analyzer, Applied  Biosystems) Figure 1
Multiplex ligation-dependent probe amplification 
(MLPA) electropherogram (ABI PRISM 310 genetic 
analyzer, Applied Biosystems). Probe mix P002 contains 
34 probes: nine control probes recognizing non-BRCA1 
sequences on various chromosomes are indicated by "c"; 
exons recognized by the BRCA1-specific probes are indicated 
by numbers (probes for both alternative exons 1...1A, 1B; 
exon 4 is not present in normal BRCA1 transcript; two 
probes specific for exon 11 are included). Note decreased 
peak heights of deleted exons.
 Deleted exons 1A - 1B - 2
          p   p p
       Normal DNA
                    Deleted exons 5 - 14
     p          p p   p    p p           p   p p    p p
  Deleted exons 21 - 22
                   p p
Deleted exons 18 - 19
                 p   p
   Deleted exons 11 - 12
                p p
         Deleted exon 20
                       p
       C  C    1A 1B 2    3   5     C   6   7  8    9  10   C  11  11 12 13  14   C    15 16 1718 19   C   20 21 22 23 24    C  C    C
Table 2: PCR primers used for long-range PCR
Affected exons – primer pair GenBank: L78833a Sizeb [kb] Sequence 5' > 3'
1A/1B-2 Puget et al. [19] ~5 TCAAGGAAATTTTCTTTTGTGC [19]
TGTGGAGTTTCCCCCATTCT [19]
5–14 19244–54463 3.6 CCTTACCTACCTACATTCAC
CTTTATGTAGGATTCAGAGTA
11–12 34650–41932 0.72 AGGAGCATTTGTTACTGAG
AGAGAGAAAAGGCCTCCTA
18–19 63463–66158 0.76 CACAGGGTCAGAGGGTAG
AGAGGATATCCTGGTTTGC
20 67298–76514 2.2 AGTCCCTGGTAGGATTCAG
TATTGAGCACTGGAGATGTG
21–22 76247–81170 1.4 TGCCACCAGCCACATG
AGCACCAGGTAATGAGTGATAA
aRegion of BRCA1 genomic sequence amplified by primer pair (nucleotide position, [GenBank: L78833]).
bDeleted allele.BMC Medical Genetics 2007, 8:32 http://www.biomedcentral.com/1471-2350/8/32
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exons 3–24 as a result of recombination between
sequences located in the intron 2 of ψBRCA1 and intron 2
of the BRCA1 gene. The promoter was shown to be absent
from this mutant allele and expression of the mutant
allele was not observed [19,25].
Deletion of the BRCA1 exons 5 to 14 was revealed by
MLPA in four high-risk, severely affected families with
young-age onset of cancer: two families with the heredi-
tary breast-ovarian cancer syndrome and two families
with only the breast cancer syndrome. Long-range PCR
confirmed a deletion of 31.5 kb of genomic DNA span-
ning more than three-quarters of the BRCA1 gene coding
sequence. This deletion interferes with the RING domain
(N-terminal zinc finger domain) of the BRCA1 protein as
well as with important interaction domains for multiple
proteins, and it is suggestive of having a negative impact
on the function of the BRCA1 protein. The exact break-
points were characterized by sequencing as
g.21716_53298del31583 (Figure 2B, Table 3). The break-
point junctions determined in all four families were iden-
tical, thus supporting the likelihood of the founder effect.
Moreover, three of the four individuals with confirmed
deletion of exons 5–14 came from the same geographical
region of the Czech Republic. Only haplotype analysis
could reveal if repeated observation of these four dele-
tions is due to the presence of founder mutation or only
to the local instability in a region [7,22].
The deletion of the second part of the exon 11 and exon
12 was found by MLPA in a family with ovarian cancer
phenotype only. Altogether, five women in two genera-
tions were affected with ovarian cancer at ages ranging
from 34 to 56 years (Figure 3). Long-range PCR confirmed
a deletion of 6.5 kb of genomic DNA spanning nearly
one-half of the BRCA1 gene coding sequence. The exact
breakpoints were characterized by sequencing as
g.34845_41405del6561 (Figure 2C, Table 3). An aberrant
splicing of mRNA that might further extend a defect on
the BRCA1 protein is suspected in this case. This deletion
lies within a central-risk region where mutations were
associated with a significantly higher ovarian/breast can-
cer ratio [41].
The deletion of the exons 18 and 19 was revealed by
MLPA in one woman diagnosed with both breast and
ovarian cancers at the ages of 52 and 59, respectively, and
with a family history of breast cancer in her second-degree
relatives. Long-range PCR confirmed a deletion of nearly
2 kb of BRCA1 genomic DNA. The exact breakpoints were
characterized by sequencing as g.63651_65590del1940
(Figure 4A, Table 3). The out-of-frame deletion of exons
18–19 is predicted to result in a truncation of the BRCA1
protein at the codon 1693. As displayed previously, most
truncating mutations of the BRCA1  gene lead to non-
sense-mediated mRNA decay and an allelic imbalance in
the expression of the mutant versus wild-type allele
[26,42].
The deletion of the exon 20 was found by MLPA in a
woman affected with breast and colorectal cancers at the
ages of 37 and 35, respectively. Her mother was affected
with bilateral breast cancer at the ages of 39 and 46. Long-
range PCR confirmed a deletion of about 7 kb of BRCA1
genomic DNA. The exact breakpoints were characterized
by sequencing as g.68764_75792del7029 (Figure 4B,
Table 3). The genomic deletion of exon 20 causes at least
in-frame deletion of exon 20 in mRNA and results in the
removing of 28 amino acids of the BRCA1 protein in posi-
tion 1732–1759. This deletion affects the highly con-
Table 3: BRCA1 germline rearrangements identified in the BRCA1 gene
BRCA1 exons 
involved
Confirmation by 
long-range PCR
Mutation 
designation 
[GenBank: 
L78833]
Suspected 
minimal effect 
on mRNAa
Fenotypeb Number of 
families 
identified
Sequence at 
breakpoint 5'/3'
1–2 yes Preisler-Adams et 
al. del 36.9 kbc [40]
not expressed [19] HBOC 1 ψ gene/gene HR 
[40]
5–14 yes g.21716_53298 
del31583
loss of 3/4 of 
coding sequence
HBC HBOC 4 LINE1/-
Part of 11–12 yes g.34845_41405 
del6561
loss of 1/2 of 
coding sequence
HOC 1 -/LINE1
18–19 yes g.63651_65590 
del1940
p.Asp1692Ala fsX2 HBOC 1 AluY/AluSp
20 yes g.68764_75792 
del7029
p.His1732_Lys175
9del
HBC 1 AluSq/AluSx
21–22 yes g.77128_80906 
del3779ins236
p.Ile1760_Thr1802
del
HBC 2 AluSx/AluJb
aInferred from change at the DNA level.
bHBC – human breast cancer, HBOC – human breast and ovarian cancer, HOC – human ovarian cancer.
cBased on the BAC clone sequence AC060780.BMC Medical Genetics 2007, 8:32 http://www.biomedcentral.com/1471-2350/8/32
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served area of the BRCA1 protein corresponding to the
linker between two BRCT (BRCA1 C-terminal) domains,
and it has been described to be involved in DNA repair
and transcription activation [43].
The next in-frame deletion of the exons 21 and 22 was
detected by MLPA in two high-risk families with heredi-
tary breast cancer phenotype only (Figure 5). Long-range
PCR confirmed a deletion of about 3.5 kb of BRCA1
genomic DNA. Sequencing of the breakpoint's region
revealed the deletion/insertion event characterized as
g.77128_80906del3779ins236 (Figure 6, Table 3). How-
ever, the in-frame deletion of exons 21–22 removes at
least 43 amino acids of the BRCA1 protein in position
1760–1802, corresponding to a part of the C-terminal
BRCT domain.
The loss of a part of the conservative domain of BRCA1
protein might have an effect on protein function and is
suspected to be causative of cancer susceptibility. Even
missense mutations located in this region (for example,
P1749R and M1775R) were described to segregate with
the disease and to have a destabilizing effect on the BRCT
domain [44]. However, the exact changes in the function
of the BRCA1 protein cannot be determined because a
functional assay is lacking. Therefore, the structural model
of deletions in the BRCT domain was constructed to help
with the interpretation of an effect on the stability of the
BRCT domain (Figure 7), which might be indirectly
related to the disease risk [44].
Inspection of the crystal structures of the BRCT repeat
region from the BRCA1  revealed that the mutant with
genomic deletion of exon 20 encodes the protein with the
missing linker region between the N-terminal and the C-
terminal BRCT repeats of BRCA1, while the in-frame dele-
tion of exons 21 and 22 results in the protein with the
missing C-terminal repeat of BRCT (Figure 7). The two
BRCT domains interact in a head-to-tail fashion, burying
about 1600 A2 of solvent-accessible surface area in the
interface [45]. The truncation of the linker or the exclu-
sion of any of the two BRCT domains will result in the
exposure of the interface and the protein's unfolding (Fig-
ure 7). It is obvious that the protein with a disrupted car-
Pedigrees of ovarian cancer family with detected deletion of  BRCA1 exons 11–12 (g.34845_41405del6561) Figure 3
Pedigrees of ovarian cancer family with detected 
deletion of BRCA1 exons 11–12 
(g.34845_41405del6561). Circles – females, squares – 
males, partially filled symbols – affected individuals, arrow – 
proband. Type of cancer and age of onset are indicated 
below each affected individual (ov – ovarian). Mutation sta-
tus: + carrier, - no carrier (wt).
pancreas 76 
ov 52  tongue 61  ov 56 
ov 36 +    -  ov 47 +    ov 34 +
     -               +     -               - 
Confirmation and characterization of the rearrangements Figure 2
Confirmation and characterization of the rearrange-
ments. (A) Confirmation of the deletion of exons 1A/1B-2 
by long-range PCR and sequencing of the breakpoints. (B) 
Confirmation of the deletion of exons 5–14 by long-range 
PCR and sequencing of the breakpoints. (C) Confirmation of 
the deletion of exons 11–12 by long-range PCR and sequenc-
ing of the breakpoints. Lanes 1+, 2+, carriers of the deletion; 
lane C-, negative control (wt); lane B, blank; lane M, marker 
(Ready-Load™ 1 Kb DNA Ladder, Invitrogen).
2
2B
  M    1+    2+   C-    B 
2A
ȥBRCA1/BRCA1 fusion sequence in patient with  
the deletion of exons 1A-1B-2 
ȥBRCA1 intron 2…                 188 bp of perfect nucleotide homology
ACCATACTGAAATATAATTATTTCAGAATTGAGTCAGTGG……………
……………TTGGTCCCAGTAATAATACCAATGTTGGTACAAGTTATCT 
                                                                                      …BRCA1 intron 2 
Preisler-Adams et al. 2006  [40]                       
 [GenBank: L78833]  34 844   41 406 
 2C
 1+  2+   C-    B    M 
M   1+    2+   C-   B 
      [GenBank: L78833]  21 715   53 299 BMC Medical Genetics 2007, 8:32 http://www.biomedcentral.com/1471-2350/8/32
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boxyl-terminal BRCT repeat region cannot fulfill its tumor
suppressor function. This structural interpretation is in
accordance with the study of Williams et al. [44,46], who
used a protease-based assay to assess the sensitivity of the
folding of the BRCT domain to an extensive set of trunca-
tion and single amino acid substitutions derived from
breast cancer screening programs. The protein can tolerate
truncations of up to eight amino acids, but further dele-
tion leads to BRCT folding defects.
It would have been interesting to determine whether
detected deletions segregate with disease in affected fami-
lies, but no informative data are available. In families with
the deletion of exons 11+12 and the deletion of exons
21+22, all affected patients tested (3 and 2) were found to
be carriers of the deletion (Figs. 3 and 5). In the cases of
the remaining eight families, as there were no other
affected individuals alive, only healthy individuals from
mainly younger generations could be tested.
Most of the previously characterized rearrangements in
the  BRCA1  gene result from an unequal homologous
recombination of Alu repeats [17]. The presence of Alu
elements revealed by the Repeat Masker program in break-
point junctions in three out of five novel deletions charac-
terized in this study supports this hypothesis. Contrary to
the Alu-mediated deletions of exons 18–19, 20 and 20–
21, no Alu repeats were found in the breakpoints of the
deletions including exons 11–12 and 5–14 (Table 3). In
these two cases, L1 repetitive sequences present near one
side of the breakpoint do not correlate with any recogniz-
able repeat motifs opposite, suggesting nonhomologous
events or other mechanisms [10,39]. The role of the L1
repetitive elements in relation to the BRCA1 intragenic
rearrangements has not yet been mentioned.
The intragenic deletions were detected in almost 6% of all
high-risk families previously considered negative for the
mutation in BRCA1 or BRCA2 genes. It represents 10.4%
of all detected BRCA1 mutations and 7.8% of all muta-
tions detected in BRCA1 and BRCA2 genes (in 290 high-
risk families tested for mutations during 1999–2006,
Table 1). This ratio is dependent on the selection of
patients and the mutation detection rate. As can be seen
from Table 1, BRCA1 rearrangements were found either in
breast plus ovarian cancer families (5 cases) or in breast
cancer families with at least one individual with breast
cancer diagnosed under 50 years of age (5 cases). The dele-
tions were identified in all three families, each with four
individuals affected by breast cancer under age 50. By con-
trast, no rearrangement was detected in families with late-
onset multiple breast cancer cases. In affected families,
Pedigrees of breast cancer family with detected deletion of  BRCA1 exons 21–22 (g.77128_80906del3779ins236) Figure 5
Pedigrees of breast cancer family with detected dele-
tion of BRCA1 exons 21–22 
(g.77128_80906del3779ins236). Circles – females, 
squares – males, partially filled symbols – affected individuals, 
arrow – proband. Type of cancer and age of onset are indi-
cated below each affected individual (br – breast). Mutation 
status: + carrier, - no carrier (wt).
br 35  br 35
+   br 36,43 + br 25,45 +
      +                 -   +                -
Confirmation and characterization of the rearrangements Figure 4
Confirmation and characterization of the rearrange-
ments. (A) Confirmation of the deletion of exons 18–19 by 
long-range PCR and sequencing of the breakpoints. (B) Con-
firmation of the deletion of exon 20 and sequencing of the 
breakpoints.Lanes 1+, 2+, carriers of the deletion; lane C-, 
negative control (wt); lane B, blank; lane M, marker (Ready-
Load™ 1 Kb DNA Ladder, Invitrogen).
 M     1+    2+   C-   B 
 M    1+    2+   C-    B 
     [GenBank: L78833] 63 650   65 591 
 4A
 4B
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ovarian cancer or at least one case of breast cancer under
age 50 seems to suggest the presence of BRCA1 gross rear-
rangement.
The proportion of intragenic BRCA1  rearrangements
could be overestimated because of a higher objective
amount of pathogenic mutations in the Czech popula-
tion.  BRCA1/2  mutations were excluded in this study
using a combination of heteroduplex analysis and protein
truncation tests. Heteroduplex analysis is aimed to detect
small insertions and deletions and not at detecting single
base changes. The protein truncation test is a convenient
method for rapidly scanning relatively large fragments for
protein-terminating variants, but it is incapable of identi-
fying some potentially risky missense variants or small in-
frame deletions located in exon 11 of BRCA1 or exon 10
and 11 of BRCA2.
Our results are in good concordance with those obtained
by studies performed in other countries: the proportion of
the  BRCA1  intragenic rearrangements is slightly higher
than are those estimated in France, Germany, Spain and in
the United States [7,20,21,23] but lower than in the pop-
ulations of Australia or New Zealand [22]. Higher propor-
tions of BRCA1 rearrangements have been observed in the
Netherlands, due to the founder mutations representing
23% of all BRCA1 mutations found [24], and in a small
population in Northern Italy [25]. On the other hand, a
study performed in Finland failed to detect any rearrange-
ments in the BRCA1 gene [47]. The most likely explana-
tion for varying prevalencies of large rearrangements is in
the differing genetic backgrounds of the populations stud-
ied. The study size and selection bias may be relevant, too.
Methodology is not supposed to be a major factor,
because the same commercially available MLPA kit is
widely used. Our results indicate that MLPA is a rapid,
reliable and sensitive technique allowing high-through-
put screening for the BRCA1 rearrangements.
Conclusion
Using MLPA technique, intragenic rearrangements were
detected in approximately 6% of the Czech high-risk fam-
ilies previously designated as BRCA1/2 mutation negative.
Six different intragenic deletions represent more than
10% of all detected BRCA1 mutations. Our results prove
the usefulness of testing for large BRCA1 rearrangements
in the Czech population. These results are important for
counseling purposes and clinical management of patients
as well as for the possibility of predictive testing of rela-
tives. MLPA testing of the BRCA2 rearrangements is now
A ribbons representation of the BRCT domain Figure 7
A ribbons representation of the BRCT domain. The 
deletion of 28 amino acids encoded by the exon 20 corre-
spond to the linker (colored red). The deletion of 43 amino 
acids encoded by the exons 21 and 22 correspond to the C-
terminal repeat of BRCT (colored blue). See Results.
Confirmation and characterization of the rearrangements Figure 6
Confirmation and characterization of the rearrange-
ments. Confirmation of the deletion of the exons 21–22 by 
long-range PCR and sequencing of the breakpoints. The dele-
tion/insertion event was characterized as 
g.77128_80906del3779ins236. Lanes 1+, 2+, carriers of the 
deletion; lane C-, negative control (wt); lane B, blank; lane M, 
marker (Ready-Load™ 1 Kb DNA Ladder, Invitrogen).
 1+   2+   C-    B     M 
  [GenBank: L78833] 
77 127  ins 236 
GACAAGGAGCATGTACACCTGTAATCCCAGCTATTTGGGA
GGCTAAGGCACGAGAATCACTTGAACCTGGGAGCTGGAGA
CTGCAGTGAGCTGAGATTGCGCCACTGCACTCCAGACTGG
CCAACAGAATCAGACAAAAAATTAGCTAGTTGTTGTGGCA 
CATGCCTGTAATCCTAGCCACTTGGGAGGCCAAGGCACAA 
GAATTGAACAAGGTTTGAACTTGGGAGGTGAAGGTTGCAG 
TGAGCAGAGATAGTGGCACTGCACTCCAGCCTGGGTGACA 
80 907 
   [GenBank: L78833] 
   ins 236 
         [GenBank: L78833]  77 127                                        ins 236 
                                         
                                     ins  236                                     [GenBank: L78833]  80 907 BMC Medical Genetics 2007, 8:32 http://www.biomedcentral.com/1471-2350/8/32
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under examination and might further improve the sensi-
tivity of testing.
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